TNFRSF8 and anaplastic large cell lymphoma: Brentuximab vedotin, a CD30-directed antibody–drug conjugate, was recently reported for a promising efficacy in CD30-expressing systemic r/r anaplastic large cell lymphoma (ALCL) with an ORR of 86% and duration of response (DOR) of 12.6 months [17].